These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 20501804

  • 1. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
    Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R.
    Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
    Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R.
    Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
    [Abstract] [Full Text] [Related]

  • 3. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC, Hu X, Kenney PA, Merrill MM, Babaian KN, Zhang XY, Maity T, Yang SF, Lin X, Wood CG.
    Clin Cancer Res; 2013 Dec 01; 19(23):6461-72. PubMed ID: 24122794
    [Abstract] [Full Text] [Related]

  • 4. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
    Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N, Springer CJ, Powles T, Nathan PD, Larkin J, Gore M, Vasudev NS, Reynolds AR.
    Mol Cancer Ther; 2016 Jan 01; 15(1):172-83. PubMed ID: 26487278
    [Abstract] [Full Text] [Related]

  • 5. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM, Mao FJ, Barnard J, Parker Y, Zamanian-Daryoush M, Pink JJ, Finke JH, Rini BI, Lindner DJ.
    Br J Cancer; 2016 Oct 11; 115(8):920-928. PubMed ID: 27560553
    [Abstract] [Full Text] [Related]

  • 6. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
    Duignan IJ, Corcoran E, Pennello A, Plym MJ, Amatulli M, Claros N, Iacolina M, Youssoufian H, Witte L, Samakoglu S, Schwartz J, Surguladze D, Tonra JR.
    Neoplasia; 2011 Jan 11; 13(1):49-59. PubMed ID: 21245940
    [Abstract] [Full Text] [Related]

  • 7. Relationships between the effect of sunitinib and immature blood vessels in metastatic renal cell cancer.
    Kim BH, Sohn JC, Ha JY, Park CH, Choe MS, Jung HR, Kim CI.
    Urol Int; 2015 Jan 11; 94(2):137-43. PubMed ID: 25138147
    [Abstract] [Full Text] [Related]

  • 8. Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma In Vivo with Susceptibility Contrast MRI.
    Robinson SP, Boult JKR, Vasudev NS, Reynolds AR.
    Cancer Res; 2017 Aug 01; 77(15):4127-4134. PubMed ID: 28566330
    [Abstract] [Full Text] [Related]

  • 9. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.
    Cancer Res; 2010 Feb 01; 70(3):1053-62. PubMed ID: 20103629
    [Abstract] [Full Text] [Related]

  • 10. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
    Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E.
    Oncogene; 2016 May 01; 35(21):2687-97. PubMed ID: 26364599
    [Abstract] [Full Text] [Related]

  • 11. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J.
    Nature; 2016 Nov 03; 539(7627):112-117. PubMed ID: 27595394
    [Abstract] [Full Text] [Related]

  • 12. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 03; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
    Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT.
    Cancer Res; 2010 Feb 01; 70(3):1063-71. PubMed ID: 20103651
    [Abstract] [Full Text] [Related]

  • 14. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM, Lowerison MR, Raven PA, Tan Z, Roberts ME, Shrestha R, Urban MW, Monjaras-Avila CU, Oo HZ, Hurtado-Coll A, Chavez-Munoz C, So AI.
    J Exp Clin Cancer Res; 2020 Feb 10; 39(1):33. PubMed ID: 32041631
    [Abstract] [Full Text] [Related]

  • 15. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G.
    Br J Cancer; 2013 Aug 06; 109(3):686-93. PubMed ID: 23839492
    [Abstract] [Full Text] [Related]

  • 16. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
    del Puerto-Nevado L, Rojo F, Zazo S, Caramés C, Rubio G, Vega R, Chamizo C, Casado V, Martínez-Useros J, Rincón R, Rodríguez-Remírez M, Borrero-Palacios A, Cristóbal I, Madoz-Gúrpide J, Aguilera O, García-Foncillas J.
    Br J Cancer; 2014 May 27; 110(11):2700-7. PubMed ID: 24786599
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, Giraldo N, Rioux-Leclercq N, Molinié V, Sibony M, Elaidi R, Teghom C, Patard JJ, Méjean A, Fridman WH, Sautès-Fridman C, de Reyniès A, Oudard S, Zucman-Rossi J.
    Clin Cancer Res; 2015 Mar 15; 21(6):1329-39. PubMed ID: 25583177
    [Abstract] [Full Text] [Related]

  • 20. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
    Dornbusch J, Zacharis A, Meinhardt M, Erdmann K, Wolff I, Froehner M, Wirth MP, Zastrow S, Fuessel S.
    PLoS One; 2013 Mar 15; 8(9):e76386. PubMed ID: 24086736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.